Erasca (ERAS) investor relations material

Key clinical updates and data

• ERAS-0015, a next-generation pan-RAS inhibitor, showed 62%-75% response rates in non-small cell lung cancer and 41% in second-line pancreatic cancer in China, with strong early data in colorectal cancer as well.

• Expansion cohorts for ERAS-0015 at 24 mg and 32 mg are enrolling; data from 20 patients per cohort will inform discussions with the FDA for potential registrational trials.

• Combination studies with pembrolizumab for first-line lung cancer and panitumumab for colorectal cancer are underway, with early signs of combinability and efficacy.

• Formal guidance for the next major data update is the first half of next year, with ongoing patient enrollment and data maturation in lung and pancreatic cohorts.

• ERAS-4001, a pan-KRAS inhibitor, will have a phase I monotherapy update in the second half of this year, focusing on safety, tolerability, and initial activity.

Competitive landscape and strategic positioning

• The RAS-targeted therapy field is evolving rapidly, with ERAS-0015 showing potential best-in-class efficacy and a differentiated safety profile.

• The company is pursuing both monotherapy and combination strategies, aiming for accelerated approval paths in key indications.

• Combination approaches are prioritized, especially in first-line settings for pancreatic, lung, and colorectal cancers, to address high unmet needs.

• The organization maintains flexibility to adapt to evolving data and market dynamics, leveraging both pan-RAS and pan-KRAS assets.

• Strategic collaborations, such as with Merck and Tango, expand combination opportunities and pipeline breadth.

Safety, tolerability, and mechanistic insights

• ERAS-0015 demonstrates lower frequency and severity of rash and GI toxicities compared to competitors, supporting its use in combinations.

• The drug’s favorable safety profile is attributed to higher CypA binding affinity and lower required doses, enhancing its therapeutic window.

• A pneumonitis event was discussed in detail, with context provided on patient history and management strategies for future cases.

• Combination with anti-EGFR agents in CRC is feasible due to manageable rash profiles, a key differentiator from other agents.

• Mechanistic advantages of ERAS-0015 are protected by a U.S. composition of matter patent through 2043, with further IP strategies under consideration.